A bill to be entitled 1 2 An act relating to stem cell research; creating s. 381.99, F.S.; providing a short title; providing definitions; 3 creating the Stem Cell Research Advisory Council and 4 Biomedical Ethics Advisory Council within the Department 5 of Health; providing for membership and terms; providing 6 7 duties and responsibilities; requiring the Secretary of Health to make grants-in-aid from the Biomedical Research 8 9 Trust Fund for stem cell research; providing requirements relating to applications for and awards of such grants-in-10 aid; providing specifications for moneys to be made 11 available from the trust fund for stem cell research 12 grants-in-aid; providing restrictions and requirements for 13 uses of funds from such grants-in-aid; providing 14 prohibitions relating to human cloning; providing for 15 16 penalties; providing an appropriation; amending s. 20.435, F.S.; revising references; amending s. 381.86, F.S.; 17 providing an exception to the Institutional Review Board 18 19 for the Stem Cell Research Advisory Council and Biomedical Ethics Advisory Council; providing an effective date. 20 21 Be It Enacted by the Legislature of the State of Florida: 22 23 Section 381.99, Florida Statutes, is created to 24 Section 1. 25 read: 26 381.99 Florida Hope Offered through Principled, Ethically 27 Sound Stem Cell Research Act. --

Page 1 of 11

SHORT TITLE. -- This section may be cited as the

CODING: Words stricken are deletions; words underlined are additions.

28

(1)

"Florida Hope Offered through Principled, Ethically Sound Stem Cell Research Act."

- (2) DEFINITIONS.--As used in this section, the term:
- (a) "Adult stem cell" means a cell found within differentiated tissue or an organ that can renew itself and give rise to the major cell types of the tissue or organ. This includes cells from the fetal to adult stages of development.
- (b) "Amniotic stem cell" means a cell extracted from human amniotic fluid or a placenta.
- (c) "Embryonic stem cell" means a cell obtained from the undifferentiated inner mass of an early stage embryo.
- (d) "Human cloning" means human asexual reproduction, accomplished by introducing nuclear material from one or more human somatic cells into a fertilized or unfertilized oocyte the nuclear material of which has been removed or inactivated so as to produce a living organism at any stage of development that is genetically virtually identical to an existing or previously existing human organism.
- (e) "Stem cell" means a cell that retains the potential to generate some or all other cell types.
- (3) STEM CELL RESEARCH ADVISORY COUNCIL.--There is created the Stem Cell Research Advisory Council within the Department of Health.
- (a)1. The advisory council shall consist of the Secretary of Health or his or her designee, who shall act as chair, and six additional members, who shall be appointed as follows:
- a. Two persons appointed by the Governor, one of whom shall be an academic researcher in the field of stem cell

Page 2 of 11

research and one of whom shall have a background in bioethics.

- b. One person appointed by the President of the Senate, who shall have a background in private-sector stem cell funding and development or public-sector biomedical research and funding.
- c. One person appointed by the Speaker of the House of Representatives, who shall have a background in private-sector stem cell funding and development or public-sector biomedical research and funding.
- d. One person appointed by the President of the Senate, who shall have a background and experience in either public-sector or private-sector stem cell research and development.
- e. One person appointed by the Speaker of the House of Representatives, who shall be an executive of a biotech company, or his or her designee.
- 2. Each member shall serve a term of 2 years commencing on October 1, 2007. No member shall serve for more than two consecutive 2-year terms; however, for the purpose of providing staggered terms, of the initial appointments, three members shall be appointed to a 1-year term and three members shall be appointed to a 2-year term. Any vacancy on the advisory council shall be filled in the same manner as the original appointment. All initial appointments shall be made by October 1, 2007. The first meeting shall take place no later than November 1, 2007. All meetings are subject to the call of the chair. Members shall meet at least twice a year or as often as necessary to discharge their duties but shall have no more than four meetings during any 12-month period. Members shall serve without compensation

85 but may

- be reimbursed for per diem and travel expenses in accordance with s. 112.061.
 - (b) The advisory council shall:
 - 1. Develop a donated funds program for recommendation to the Secretary of Health to encourage the development of funds other than state appropriations for human adult stem cell research in the state.
 - 2. Examine and identify specific ways to improve and promote for-profit and not-for-profit human adult stem cell and related research in the state, including, but not limited to, identifying both public and private funding sources for such research, maintaining existing human adult stem cell-related businesses, recruiting new human adult stem cell-related businesses to the state, and recruiting scientists and researchers in such fields to the state and state universities.
 - 3. Develop a biomedical research grant program for recommendation to the Secretary of Health that shall provide grants-in-aid to eligible state institutions for the advancement of human adult stem cell research.
 - 4. Develop, no later than December 1, 2007, an application for grants-in-aid under this section for recommendation to the Secretary of Health for the purpose of conducting human adult stem cell research.
 - 5. Review applications from eligible institutions for grants-in-aid on and after December 1, 2007, and provide to the Secretary of Health recommendations for grant awards.
 - 6. Review the stem cell research conducted by eligible

Page 4 of 11

institutions that receive such grants-in-aid.

- (c) The advisory council shall submit an annual progress report on the status of biomedical research in the state to the Florida Center for Universal Research to Eradicate Disease and to the Governor, the Secretary of Health, the President of the Senate, and the Speaker of the House of Representatives by June 30. The report must include:
- 1. The amount of grants-in-aid awarded to eligible institutions from the Biomedical Research Trust Fund.
 - 2. The names of the recipients of such grants-in-aid.
- 3. The current status and progress of stem cell research in the state.
- 4. A list of research projects supported by grants-in-aid awarded under the program.
- 5. A list of publications in peer-reviewed journals involving research supported by grants-in-aid awarded under the program.
- 6. The total amount of biomedical research funding currently flowing into the state.
- 7. New grants for biomedical research that were funded based on research supported by grants-in-aid awarded under the program.
- 8. All other materials the advisory council deems advisable to include.
- (d) Advisory council members shall disclose any conflict of interest or potential conflict of interest to the Secretary of Health.
 - (e) The Department of Health shall provide administrative

Page 5 of 11

staff to assist the advisory council in developing the application for the grants-in-aid, reviewing the applications, preparing the written consent form described in paragraph (6)(b), and performing other administrative functions as the advisory council requires.

- (4) BIOMEDICAL ETHICS ADVISORY COUNCIL. -- There is created within the Department of Health the Biomedical Ethics Advisory Council.
- (a)1. The advisory council shall consist of the Secretary of Health or his or her designee, who shall act as chair, and six additional members, who shall be appointed as follows:
 - a. Two persons appointed by the Governor.
 - b. One person appointed by the President of the Senate.
- c. One person appointed by the Speaker of the House of Representatives.
- $\underline{\text{d.}}$ One person appointed by the Minority Leader of the Senate.
- e. One person appointed by the Minority Leader of the House of Representatives.
- 2. All members must demonstrate knowledge and understanding of the ethical, medical, and scientific implications of stem cell research and should also demonstrate knowledge of related fields, including, but not limited to, genetics, cellular biology, and embryology. Each member shall serve a term of 4 years commencing on October 1, 2007; however, for the purpose of providing staggered terms, of the initial appointments, three members shall be appointed to a 2-year term and three members shall be appointed to a 4-year term. No member

Page 6 of 11

CODING: Words stricken are deletions; words underlined are additions.

shall serve for more than two consecutive terms. Any vacancy on the advisory council shall be filled in the same manner as the original appointment. All initial appointments shall be made by October 1, 2007. The first meeting shall take place no later than November 1, 2007. All meetings are subject to the call of the chair. Members shall meet at least twice a year or as often as necessary to discharge their duties but shall have no more than one meeting per month during any 12-month period. Members shall serve without compensation but may be reimbursed for per diem and travel expenses in accordance with s. 112.061.

- (b) The advisory council shall review all stem cell research that is funded or supported in any manner through the Biomedical Research Trust Fund to ensure the adherence to ethical and safety guidelines and procedures as set forth by federal ethical standards established by the United States

 Department of Health and Human Services.
 - (5) BIOMEDICAL RESEARCH TRUST FUND AND GRANTS-IN-AID.--
- (a) The Secretary of Health shall make grants-in-aid from the Biomedical Research Trust Fund in accordance with the provisions of this section.
- (b) The Department of Health shall require any applicant for a grant-in-aid under this section, for the purpose of conducting stem cell research, to submit a complete description of the applicant's organization, the applicant's plans for stem cell research, the applicant's proposed funding for such research from sources other than the state, and the applicant's proposed arrangements concerning financial benefits to the state as a result of any patent, royalty payment, or similar right

resulting from any stem cell research made possible by the awarding of the grant-in-aid. The Stem Cell Research Advisory

Council shall provide recommendations to the Secretary of Health with respect to awarding such grants-in-aid after considering the recommendations of the Biomedical Ethics Advisory Council.

- (c) Beginning with the 2007-2008 fiscal year, and for 10 consecutive years thereafter, not less than \$20 million shall be made available annually from the Biomedical Research Trust Fund within the Department of Health for grants-in-aid to eligible institutions for the purpose of conducting adult stem cell research pursuant to this section. Up to 15 percent of the funds may be used for administrative costs. Any unexpended funds not used for grants-in-aid during the current fiscal year shall be carried forward for the following fiscal year to fund the grants-in-aid.
 - (6) USE OF FUNDS; REQUIREMENTS AND RESTRICTIONS. --
- (a) Funds provided under this section may only be used for research involving:
- 1. Human adult stem cells, including, but not limited to, adult stem cells derived from umbilical cord blood and bone marrow. Funding for research may be given for human adult stem cells derived from postmortem tissues, other than from medically induced abortions. Funds may be used for studies of human adult stem cells obtained from either normal or transformed tissues.
- 2. Amniotic stem cells extracted from human amniotic fluid or placentas that are otherwise discarded after birth.
- (b) Amniotic and adult stem cell material may only be donated for research purposes with the informed consent of the

Page 8 of 11

donor.

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

- (c) No funds shall be used for research with human embryonic stem cells that are derived by a process entailing the donor embryo's death or destruction.
 - (7) HUMAN CLONING; PROHIBITION; PENALTIES. --
 - (a) It is unlawful for any person to knowingly:
 - 1. Perform or attempt to perform human cloning;
- 2. Participate or assist in an attempt to perform human cloning; or
- 3. Ship or receive for any purpose an embryo produced by human reproductive cloning or any product derived from such embryo.
- (b) A person who violates paragraph (a) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084.
- (8) CONTINUING APPROPRIATION.--Beginning in fiscal year 2007-2008, the sum of \$20 million is appropriated annually from recurring funds in the General Revenue Fund to the Biomedical Research Trust Fund within the Department of Health for the purpose of carrying out the provisions of this section. The amount of funds appropriated shall not exceed \$200 million for the 10-year period beginning in fiscal year 2007-2008 and ending in fiscal year 2016-2017.
- Section 2. Paragraph (h) of subsection (1) of section 20.435, Florida Statutes, is amended to read:
 - 20.435 Department of Health; trust funds.--
- (1) The following trust funds are hereby created, to be administered by the Department of Health:

Page 9 of 11

CODING: Words stricken are deletions; words underlined are additions.

(h) Biomedical Research Trust Fund.

- 1. Funds to be credited to the trust fund shall consist of funds deposited pursuant to <u>ss. s.</u> 215.5601, 288.955, and 381.99 and any other funds appropriated by the Legislature. Funds shall be used for the purposes of the James and Esther King Biomedical Research Program, and the William G. "Bill" Bankhead, Jr., and David Coley Cancer Research Program, and the Florida Hope Offered through Principled, Ethically Sound Stem Cell Research Act as specified in ss. 215.5602, 288.955, and 381.922, and 381.99. The trust fund is exempt from the service charges imposed by s. 215.20.
- 2. Notwithstanding the provisions of s. 216.301 and pursuant to s. 216.351, any balance in the trust fund at the end of any fiscal year shall remain in the trust fund at the end of the year and shall be available for carrying out the purposes of the trust fund. The department may invest these funds independently through the Chief Financial Officer or may negotiate a trust agreement with the State Board of Administration for the investment management of any balance in the trust fund.
- 3. Notwithstanding s. 216.301 and pursuant to s. 216.351, any balance of any appropriation from the Biomedical Research Trust Fund which is not disbursed but which is obligated pursuant to contract or committed to be expended may be carried forward for up to 3 years following the effective date of the original appropriation.
- 4. The trust fund shall, unless terminated sooner, be terminated on July 1, 2008.

Page 10 of 11

Section 3. Subsection (1) of section 381.86, Florida Statutes, is amended to read:

381.86 Institutional Review Board. --

281

282

283

284

285

286

287

288

289

290

291

292

- (1) The Institutional Review Board is created within the Department of Health in order to satisfy federal requirements under 45 C.F.R. part 46 and 21 C.F.R. parts 50 and 56 that an institutional review board review all biomedical and behavioral research on human subjects which is funded or supported in any manner by the department, except that a separate Stem Cell Research Advisory Council and Biomedical Ethics Advisory Council shall be appointed under s. 381.99.
 - Section 4. This act shall take effect July 1, 2007.